This content is viewable by members only. Visit MY ACCOUNT on the top menu to log in or to register for a 30 day free trial or purchase a subscription for UV Reporter 1 Year Single Membership or UV Reporter 1 Year Group Membership - $189 for first member and $25 for each additional member.
Aytu BioPharma publishes in vitro data demonstrating UV-A light increases mitochondrial anti-viral signaling protein within cells
ENGLEWOOD, CO / May 17, 2021 / Aytu BioPharma, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, reported financial results for the fiscal third quarter ended March 31, 2021 and provided recent business highlights. The Company also disclosed that in May 2021, Aytu announced the publication of in vitro data related to the ultraviolet A (UVA) light used in the Healight™ UVA endotracheal catheter technology in bioRxiv. The manuscript titled “Ultraviolet-A light increases mitochondrial anti-viral signaling protein via cell-cell communication” concluded that UVA light increases the expression of mitochondrial antiviral-signaling (MAVS)…
Published in Informational
More from InformationalMore posts in Informational »
- Congressman Sanford D. Bishop Jr. Presents Federally Funded Check to Leesburg, GA to Include UV Wastewater Treatment
- Westmoreland, PA Approves $31 M in Water Treatment Plant Upgrades Including Ultraviolet Disinfection System
- Bioaerosol Chamber Disinfected with Ultraviolet Light Between Studies
- Morro’s Bay, CA Has $160M Water Treatment Online Ahead of Schedule and Includes UV Advanced Oxidation
- PURO UV, Ushio and Johnson Controls Join Forces to Further the Scientific Research of Far UV-C and Validate its Benefits to IAQ